


## CLAIMS

1. Use of an  $\alpha$ -aminoamide of formula (I):



wherein:

A is a  $-(\text{CH}_2)_m-$  or  $-(\text{CH}_2)_n-\text{X}-$ , wherein m is 1 or 2; n is zero, 1 or 2; and X is  $-\text{O}-$ ,  $-\text{S}-$  or  $-\text{NH}-$ ;

R is a furyl, thienyl, or pyridyl ring or a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_3$  alkoxy and trifluoromethyl;

$\text{R}_1$  is hydrogen or  $\text{C}_1$ - $\text{C}_3$  alkyl;

$\text{R}_2$  is hydrogen or  $\text{C}_1$ - $\text{C}_2$  alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from  $\text{C}_1$ - $\text{C}_3$  alkyl, halogen, hydroxy,  $\text{C}_1$ - $\text{C}_2$  alkoxy or trifluoromethyl;

$\text{R}_3$  is hydrogen or  $\text{C}_1$ - $\text{C}_3$  alkyl;

if the case, either as a single isomer, or as a mixture thereof, or a pharmaceutically acceptable derivative thereof;

in the manufacture of a medicament for the treatment of head pain conditions involving a cerebral vasodilatation mechanism.

2. Use of an  $\alpha$ -aminoamide according to claim 1, wherein in formula (I):

A is a group selected from  $-\text{CH}_2-\text{CH}_2-$ ,  $-\text{CH}_2-\text{O}-$ ,  $-\text{CH}_2-\text{S}-$ ,  $-\text{CH}_2-\text{CH}_2-\text{O}-$ ;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen,  $\text{C}_1$ - $\text{C}_3$  alkyl or a methoxy group; or a thienyl ring;

$\text{R}_1$  is hydrogen or  $\text{C}_1$ - $\text{C}_2$  alkyl;

$\text{R}_2$  is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by  $\text{C}_1$ - $\text{C}_2$  alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

$\text{R}_3$  is hydrogen or  $\text{C}_1$ - $\text{C}_2$  alkyl.

BEST AVAILABLE COPY

AMENDED SHEET

3. Use of an  $\alpha$ -aminoamide according to claim 1 or 2, wherein in formula (I):

A is  $-\text{CH}_2-\text{O}-$ ,  $-\text{CH}_2-\text{S}-$  or  $-\text{CH}_2-\text{CH}_2-$ ;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

$\text{R}_1$  is hydrogen;

$\text{R}_2$  is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

$\text{R}_3$  is hydrogen or methyl.

4. Use of an  $\alpha$ -aminoamide according to claim 1, wherein the  $\alpha$ -aminoamide is selected from:

2-(4-benzyloxybenzylamino)propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-(4-(2-thienylmethylenoxy)benzylamino)-propanamide;

2-[4-(2-(3-fluorophenyl)ethyl)benzylamino]-propanamide;

2-[4-benzylthiobenzylamino]-propanamide;

2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

**BEST AVAILABLE COPY**

2-[4-benzyloxybenzylamino] N-methylbutanamide;  
2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;  
2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;  
2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;  
2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;  
2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-  
acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide;

if the case, either as a single isomer or as a mixture thereof, or a pharmaceutically acceptable derivative thereof.

5. Use of an  $\alpha$ -aminoamide according to any of the previous claims, wherein the  $\alpha$ -aminoamide is selected from: (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide, (S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide and (S)-(+)-2-[4-(3-chlorobenzyloxy)benzylamino]-propanamide.

6. Use according to any of the previous claims, wherein head pain conditions are both primary and secondary headache disorders.

7. Use according to any of the previous claims, wherein head pain conditions include migraine, headache, hemicrania.

8. Use according to any of the previous claims, wherein migraine is acute, transformed or vascular migraine; headache is acute, cluster, evolutive or tension type headache; hemicrania is chronic paroxysmal hemicrania.

9. A method for the treatment of head pain conditions involving a cerebral vasodilatation mechanism in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one  $\alpha$ -aminoamide of formula (I) as defined in any of claims 1 to 5.

10. A method according to the previous claim, wherein the mammal is administered a dose of the  $\alpha$ -aminoamide of formula (I)

BEST AVAILABLE COPY

AMENDED SHEET

as defined in any of claims 1 to 5 which ranges from about 0.05 to 20 mg/kg body weight per day.

11. A method according to claim 9 or 10, wherein the mammal is administered a dose of the  $\alpha$ -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 10 mg/kg day.

12. A method according to any of claims from 9 to 11, wherein the mammal is administered a dose of the  $\alpha$ -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 5 mg/kg day.

13. A method according to any of claims from 9 to 12, wherein the head pain conditions are as defined in any of claims 6 to 8.

BEST AVAILABLE COPY